Integra LifeSciences (NASDAQ:IART) Releases Earnings Results

Integra LifeSciences (NASDAQ:IART) posted its earnings results on Monday. The life sciences company reported $0.41 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.02, Briefing.com reports. The firm had revenue of $380.80 million for the quarter, compared to analysts’ expectations of $375.81 million. Integra LifeSciences had a return on equity of 14.07% and a net margin of 1.51%. The company’s quarterly revenue was down .4% on a year-over-year basis. During the same period last year, the firm earned $0.76 EPS.

Integra LifeSciences Stock Up 25.1 %

Shares of NASDAQ:IART opened at $24.12 on Tuesday. The business has a 50-day moving average price of $18.62 and a 200 day moving average price of $24.46. Integra LifeSciences has a 12-month low of $16.81 and a 12-month high of $45.42. The company has a current ratio of 3.39, a quick ratio of 2.10 and a debt-to-equity ratio of 1.17. The company has a market capitalization of $1.87 billion, a price-to-earnings ratio of 83.17, a PEG ratio of 0.66 and a beta of 1.08.

Wall Street Analysts Forecast Growth

IART has been the subject of a number of recent analyst reports. Morgan Stanley boosted their price objective on Integra LifeSciences from $24.00 to $27.00 and gave the company an “underweight” rating in a research report on Monday, July 15th. Bank of America cut their price target on shares of Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a report on Monday, October 7th. Truist Financial decreased their price objective on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a report on Monday, October 14th. BTIG Research raised shares of Integra LifeSciences from a “sell” rating to a “neutral” rating in a research note on Monday, October 7th. Finally, Citigroup decreased their price target on shares of Integra LifeSciences from $20.00 to $16.00 and set a “sell” rating on the stock in a research note on Tuesday, October 1st. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $26.50.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.